CONCLUSION
In the current study, we identified FGFR3 gene amplification (10 copies) in a patient with gastric adenocarcinoma. Targeting FGFR3 amplification with Pazopanib in combination with Gemcitabine and Pemetrexed yielded significant durable response. These results suggest that ETA-guided combination regimens of targeted and cytotoxic agents targeting FGFR3 is an efficient treatment strategy in FGFR3 amplified gastric cancer patients.
ACKNOWLEDGEMENTS
The authors acknowledge the patient and his family for consenting to publication of the deidentified case details. The contributions of staff from HCG Manavata Cancer centre as well as of Datar Cancer Genetics are acknowledged.